¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cyclic adenosine monophosphate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cyclic schizophrenia
    ¼øÈ¯ÇüÁ¤½ÅºÐ¿­º´
  • cyclic strabismus
    ÁÖ±â»ç½Ã
  • cyclic vomiting
    Áֱ⼺±¸Åä
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cyclic spasm
    Áֱ⿬Ãà
  • cyclic strabismus
    ÁÖ±â»ç½Ã
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adenosine diphosphate
    ÀÌÀÎ»ê¾Æµ¥³ë½Å
  • adenosine diphosphate =ADP
    ÀÌÀÎ»ê¾Æµ¥³ë½Å.
  • adenosine diphosphate(adp)
    ¾Æµ¥³ë½ÅÀÌÀλê(¡­ì£ìÝß«)
  • adenosine triphosphatase
    ¾Æµ¥³ë½Å »ïÀλêÈ¿¼Ò
  • adenosine triphosphatase
    ¾Æµ¥³ë½Å Æ®¸®Æ÷½ºÆÄÅ×À̽º
  • adenosine triphosphate
    »ïÀÎ»ê¾Æµ¥³ë½Å
  • adenosine triphosphate =ATP
    »ïÀÎ»ê ¾Æµ¥³ë½Å.
  • adenosine triphosphate(atp)
    ¾Æµ¥³ë½Å»ïÀλê(¡­ß²ìÝß«)
  • adenosine,deficiency
    °áÇÌÁõ(ÌÀù¹ñø)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adenosine triphosphatase
    ¾Æµ¥³ë½Å Æ®¸®Æ÷½ºÆÄÅ×À̽º
  • adenosine triphosphate
    »ïÀÎ»ê¾Æµ¥³ë½Å
  • adenosine triphosphate =ATP
    »ïÀÎ»ê ¾Æµ¥³ë½Å.
  • adenosine triphosphate(atp)
    ¾Æµ¥³ë½Å»ïÀλê(¡­ß²ìÝß«)
  • adenosine,deficiency
    °áÇÌÁõ(ÌÀù¹ñø)
  • cAMP=>cyclic AMP
    ȯ½ÄAMP
  • cyclic AMP
    °í¸® AMP
  • cyclic AMP-dependent kinase
    °í¸® AMP ÀÇÁ¸¼º Ű³ªÁ¦
  • cyclic GMP
    °í¸® GMP.
  • cyclic adenosin 3-5-phosphate
    °í¸®¾Æµ¥³ë½Å 3-5Àλ꿰.
  • cyclic adenosinemonophosphate
    °í¸® AMP.
  • cyclic bleeding
    Áֱ⼺ ÃâÇ÷(ñÎÑ¢àõõóúì).
  • cyclic buccal ulceration
    Áֱ⼺ ±¸°­±Ë¾ç(ñÎÑ¢àõϢ˷Ï÷åË).
  • cyclic compound
    °í¸®Çü ȯ½ÄÈ­ÇÕ¹°(¡­úþü»ãÒûùùêÚª).
  • cyclic distribution
    ¼øÈ¸Çü ºÐÆ÷(ËàÌ·Ì´ËÓ̰).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • nucleoside monophosphate kinase
    ÀÏÀλê(ìé×òß«) ´©Å¬¸®¿À»çÀ̵å Ä«À̳×À̽º
  • cyclic adenylic acid °í¸® ¾Æµ¥´Ñ»ê(ß«)
    "(ÔÒ)(ÔÒ) adenosine-3',5'-cyclic monophosphate,"
  • cyclic AMP receptor protein
    °í¸®AMP ¼ö¿ëü ´Ü¹éÁú(áôé»ô÷Ó±ÛÜòõ)
  • cyclic electron flow
    ¼øÈ¯(âàü») ÀüÀÚ(ï³í­) È帧
  • cyclic GMP
    "°í¸® GMP (ÔÒ) guanosine-3',5'-cyclic monophosphate,"
  • cyclic metabolic pathway
    ȸ·Î ´ë»ç°æ·Î(üÞÖØÓÛÞóÌèÖØ)
  • cyclic peptide
    °í¸®ÆéŸÀ̵å
  • cyclic permutation
    "¼øÈ¯¼ø¿­(âàü»â÷æê), (ÔÒ) circular permutation"
  • cyclic photophosphorylation
    ¼øÈ¯ ±¤ÀλêÈ­(âàü»ÎÃìÝß«ûù)
  • cyclic symmetry
    "°í¸®´ëĪ(Óßöà), (ÔÒ) rotational symmetry"
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CREM center for rural emergency medicine; cyclic adenosine monophosphate-response element modulator
NcAMP nephrogenous cyclic adenosine monophosphate
PRKAR protein kinase, cyclic adenosine monophosphate-dependent, regulatory
PRKAR1A protein kinase, cyclic adenosine monophosphate-dependent, regulatory, type 1 alpha
dAMP deoxyadenosine monophosphate; deoxyadenylate adenosine monophosphate
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
8 Br-cAMP 8 Bromo adenosine 3', 5' cyclic monophosphate
8-CPT-cAMP 8-(chlorophenylthio)-adenosine 3',5'-cyclic monophosphate
8-Br-cAMP 8-Bromo-cyclic adenosine monophosphate
cyclic GMP Cyclic guanosine 3',5' monophosphate
cyclic GMP Cyclic guanosine monophosphate
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cyclic spasm
    Áֱ⠿¬Ãà
  • idiopathic cyclic neutropenia
    Ư¹ß¼º Áֱ⼺ È£Áß±¸ °¨¼ÒÁõ
    ¸¸¼ºÇüÀÇ È£Áß±¸ °¨¼ÒÁõÀ¸·Î¼­, ÁÖ±âÀûÀ¸·Î ÀϾ´Â Àç¹ßÀ» Ư¡À¸·Î Çϸç, º´°¨, ¹ß¿­, ±¸³»¿° ¹× °¢Á¾ÀÇ °¨¿°À» µ¿¹ÝÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
nucleoside-monophosphate A nucleotide, e.g., AMP.
(05 Mar 2000)
deoxycytidine monophosphate <chemical> Deoxycytidine (dihydrogen phosphate). A deoxycytosine nucleotide containing one phosphate group esterified to the deoxyribose moiety in the 2'-,3'- or 5- positions.
Chemical name: 5'-Cytidylic acid, 2'-deoxy-
(12 Dec 1998)
dolichol monophosphate mannose <chemical> A lipophilic glycosyl carrier of the monosaccharide mannose in the biosynthesis of oligosaccharide phospholipids and glycoproteins.
Chemical name: beta-D-Mannopyranose, 1-ester with dolichol dihydrogen phosphate
(12 Dec 1998)
inosine monophosphate <chemical> Inosine 5'-monophosphate. A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety.
Chemical name: 5'-Inosinic acid
(12 Dec 1998)
orotidine 5'-monophosphate Orotidine 5'-monophosphate;an intermediate in the biosynthesis of the pyrimidine nucleosides (cytidine and uridine) that are found in nucleic acids.
Synonym: orotidine 5'-monophosphate.
(05 Mar 2000)
terpenyl monophosphate hydrolase <enzyme> Hydrolyzes bornyl phosphate to borneol
Registry number: EC 3.1.3.-
(26 Jun 1999)
thiamine monophosphate <chemical> Thiamine dihydrogen phosphate ester. The monophosphate ester of thiamine.
Synonym: monophosphothiamine; vitamin b1 monophosphate.
Chemical name: Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-4-methyl-5-(2-(phosphonooxy)ethyl)-, chloride
(12 Dec 1998)
thymidine 5'-monophosphate A major constituent of DNA.
Synonym: thymidine 5'-monophosphate, thymine nucleotide.
(05 Mar 2000)
thymidine monophosphate <chemical> 5-thymidylic acid. A thymine nucleotide containing one phosphate group esterified to the deoxyribose moiety.
Chemical name: 5'-Thymidylic acid
(12 Dec 1998)
uridine 5'-monophosphate Uridine esterified by phosphoric acid on one or more sugar hydroxyl groups; UMP is typically uridine 5'-monophosphate; 2' and 3' derivatives also occur; precursor for the biosynthesis of other pyrimidine nucleotides.
Synonym: UMP synthase, uridine 5'-monophosphate.
Uridylic acid synthase, a bifunctional enzyme that contains the activities of both orotate phosphoribosyltransferase and orotidine-5'-monophosphate decarboxylase; catalyses a key step in pyrimidine biosynthesis; a deficiency of this enzyme leads to orotic aciduria.
(05 Mar 2000)
uridine 5'-monophosphate synthase <chemical> Consists of orotate phosphoribosyltransferase EC 2.4.2.10 and orotidylate decarboxylase EC 4.1.1.23
Chemical name: synthase, uridylate
Synonym: ump synthase, uridine 5'-phosphate synthase, uridylate synthase
(26 Jun 1999)
uridine monophosphate <chemical> 5'-uridylic acid. A uracil nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.
Chemical name: 5'-Uridylic acid
(12 Dec 1998)
uridine monophosphate kinase <enzyme> Catalyses the phosphorylation of ump to udp; an aspect of EC 2.7.4.4
Registry number: EC 2.7.4.-
Synonym: ump kinase, uridine-5-monophosphate kinase, uridylate kinase
(26 Jun 1999)
5-methyldeoxycytidine monophosphate aminohydrolase <enzyme> Forms thymidylate; does not act on dcmp
Registry number: EC 3.5.4.-
Synonym: 5mdcmp aminohydrolase
(26 Jun 1999)
adenosine <biochemistry> A ribonucleotide which consists of the nitrogenous base adenine linked to the sugar ribose.
<drug> A cardiac drug used in terminating PSVT involving reentry pathways that include the AV node or Wolff-Parkinson-White syndrome. For atrial flutter, atrial fibrillation, atrial or ventricular tachycardias, adenosine may produce transient AV block that may help identify the rhythm.
Pharmacologic action: Endogenous purine nucleoside that depresses AV node and sinus node activity. Brief duration of action (1-2 min).
Dose: Rapid 6 mg IV bolus over 1-3 sec. May repeat at 12 mg IV bolus within 1-2 min Patients taking theophylline may require larger doses. Use a smaller dose with cardiac transplant patients.
Potential complications: Common but transient - flushing, dyspnea, chest pain, bradycardia, and ventricular ectopy. Theophylline (and caffeine) blocks adenosine's effects. Dipyridamole potentiates adenosine's effects. Use other agents to avoid these drug interactions.
(15 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á